{"id":10429,"date":"2019-07-18T10:28:45","date_gmt":"2019-07-18T10:28:45","guid":{"rendered":"http:\/\/www.sib.it\/?p=10429"},"modified":"2019-07-18T12:34:08","modified_gmt":"2019-07-18T12:34:08","slug":"sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu","status":"publish","type":"post","link":"https:\/\/sib.arvis.dev\/en\/newsletter\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\/","title":{"rendered":"SIBprima July 2019 – From PCT application to Italian patent – Revised rules of EPO Boards of Appeal – Pharma patents in EU"},"content":{"rendered":"\n\n\n\n\n\n\n\n\n
\"from<\/span><\/td>\n<\/tr>\n
PATENTS IN ITALY<\/span>
\n<\/strong><\/span><\/p>\n

Italy confirms new direct route from international PCT application to national patent<\/a><\/span><\/h2>\n

Applicants will soon be able to obtain patent protection in Italy directly via an international PCT application. (more<\/a>) <\/em><\/span><\/td>\n<\/tr>\n

EUROPEAN PATENTS – OFFICE PRACTICE<\/span>
\n<\/strong><\/span><\/p>\n

Italy completes implementation of unitary patent laws \u2013 but unitary patent is not in force<\/a><\/span><\/h3>\n

A revised version of the Rules of Procedure of the Boards of Appeal of the European Patent Office will come into force on 1 January 2020: read our quick summary of significant changes and what they mean in practice. (more<\/a>) <\/em><\/span><\/td>\n

\"European<\/span><\/td>\n<\/tr>\n
\"SPC<\/span><\/td>\nPHARMA PATENTS IN EUROPE<\/span>
\n<\/strong><\/span><\/p>\n

New \u201cSPC waiver\u201d EU regulation in force as of 1 July 2019<\/a><\/span><\/h3>\n

A new \u201cSPC waiver\u201d EU regulation entered into force on 1 July 2019, allowing third parties to start manufacturing medicinal products protected by an SPC before expiry of the SPC, at certain conditions.(more<\/a>) <\/em><\/span><\/td>\n<\/tr>\n

ITALY – CASE LAW<\/span>
\n<\/strong><\/span><\/p>\n

Italian court awards damages in copyright dispute over Audrey Hepburn\u2019s image<\/a><\/span><\/h3>\n

Italian court orders the manufacturer of unauthorised Audrey Hepburn t-shirts to pay damages to the actress\u2019 heirs: under Italian copyright law a person\u2019s portrait cannot be reproduced for commercial or advertising purposes without the authorisation of either the person or the heirs, regardless of whether the person is renowned. (more<\/a>)<\/em><\/span><\/td>\n

\u00a0\"Audrey<\/span><\/td>\n<\/tr>\n
\"Registrazione<\/span><\/td>\n\u00a0EU COURTS – CASE LAW<\/strong><\/span><\/span><\/p>\n

Footballer scores against free rider in NEYMAR bad faith trademark dispute<\/a><\/span><\/h3>\n

EU General Court shows red card to the holder of a EU trademark for the word NEYMAR: sufficient objective circumstances justified the finding that the trademark application was filed with dishonest intentions. (more<\/a>)<\/em><\/span><\/td>\n<\/tr>\n

RECOGNITIONS<\/strong><\/span><\/p>\n

4 SIB partners listed in Patent 1000 2019 for patent prosecution work<\/a><\/span><\/h3>\n

Antonio Mario Pizzoli, Elisabetta Papa, Claudio Germinario and Emanuele Concone are all listed individually in Patent 1000. Find out why. (more<\/a>)<\/em><\/span><\/td>\n

\"migliori<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u200b<\/p>\n","protected":false},"excerpt":{"rendered":"

PATENTS IN ITALY Italy confirms new direct route from international PCT application to national patent Applicants will soon be able to obtain patent protection in Italy directly via an international PCT application. (more) EUROPEAN PATENTS – OFFICE PRACTICE Italy completes implementation of unitary patent laws \u2013 but unitary patent is not in force A revised […]<\/p>\n","protected":false},"author":4,"featured_media":10396,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[16],"tags":[],"class_list":["post-10429","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-newsletter"],"acf":[],"yoast_head":"\n[:en]SIBprima July 2019 - From PCT application to Italian patent - Revised rules of EPO Boards of Appeal - Pharma patents in EU[:] -<\/title>\n<meta name=\"description\" content=\"SIBprima July 2019 - From PCT application to Italian patent \u2013 Revised rules of EPO Boards of Appeal \u2013 Pharma patents in EU - Join our mailing list!\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"[:en]SIBprima July 2019 - From PCT application to Italian patent - Revised rules of EPO Boards of Appeal - Pharma patents in EU[:] -\" \/>\n<meta property=\"og:description\" content=\"SIBprima July 2019 - From PCT application to Italian patent \u2013 Revised rules of EPO Boards of Appeal \u2013 Pharma patents in EU - Join our mailing list!\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sib.arvis.dev\/en\/newsletter\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-18T10:28:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-07-18T12:34:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sib.arvis.dev\/wp-content\/uploads\/2019\/07\/Copertina.png\" \/>\n\t<meta property=\"og:image:width\" content=\"650\" \/>\n\t<meta property=\"og:image:height\" content=\"468\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Laura Ercoli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Laura Ercoli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/newsletter\\\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/newsletter\\\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\\\/\"},\"author\":{\"name\":\"Laura Ercoli\",\"@id\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/#\\\/schema\\\/person\\\/3988cde84153da4b745510f0712d395b\"},\"headline\":\"SIBprima July 2019 – From PCT application to Italian patent – Revised rules of EPO Boards of Appeal – Pharma patents in EU\",\"datePublished\":\"2019-07-18T10:28:45+00:00\",\"dateModified\":\"2019-07-18T12:34:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/newsletter\\\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\\\/\"},\"wordCount\":306,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/newsletter\\\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sib.arvis.dev\\\/wp-content\\\/uploads\\\/2019\\\/07\\\/Copertina.png\",\"articleSection\":[\"Newsletter\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/newsletter\\\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/newsletter\\\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\\\/\",\"url\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/newsletter\\\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\\\/\",\"name\":\"[:en]SIBprima July 2019 - From PCT application to Italian patent - Revised rules of EPO Boards of Appeal - Pharma patents in EU[:] -\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/newsletter\\\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/newsletter\\\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sib.arvis.dev\\\/wp-content\\\/uploads\\\/2019\\\/07\\\/Copertina.png\",\"datePublished\":\"2019-07-18T10:28:45+00:00\",\"dateModified\":\"2019-07-18T12:34:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/#\\\/schema\\\/person\\\/3988cde84153da4b745510f0712d395b\"},\"description\":\"SIBprima July 2019 - From PCT application to Italian patent \u2013 Revised rules of EPO Boards of Appeal \u2013 Pharma patents in EU - Join our mailing list!\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/newsletter\\\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/newsletter\\\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/newsletter\\\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\\\/#primaryimage\",\"url\":\"https:\\\/\\\/sib.arvis.dev\\\/wp-content\\\/uploads\\\/2019\\\/07\\\/Copertina.png\",\"contentUrl\":\"https:\\\/\\\/sib.arvis.dev\\\/wp-content\\\/uploads\\\/2019\\\/07\\\/Copertina.png\",\"width\":650,\"height\":468,\"caption\":\"from PCT application to Italian patent\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/newsletter\\\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/home\\\/?lang=en\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"(English) SIBprima July 2019 – From PCT application to Italian patent – Revised rules of EPO Boards of Appeal – Pharma patents in EU\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/\",\"name\":\"\",\"description\":\"Intellectual Property since 1882\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/#\\\/schema\\\/person\\\/3988cde84153da4b745510f0712d395b\",\"name\":\"Laura Ercoli\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b585753dc2b199a95f18adfc63fe4f51a86794b5f62f6d6087ebb3cbe49a1fbc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b585753dc2b199a95f18adfc63fe4f51a86794b5f62f6d6087ebb3cbe49a1fbc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b585753dc2b199a95f18adfc63fe4f51a86794b5f62f6d6087ebb3cbe49a1fbc?s=96&d=mm&r=g\",\"caption\":\"Laura Ercoli\"},\"url\":\"https:\\\/\\\/sib.arvis.dev\\\/en\\\/author\\\/lercoli\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"[:en]SIBprima July 2019 - From PCT application to Italian patent - Revised rules of EPO Boards of Appeal - Pharma patents in EU[:] -","description":"SIBprima July 2019 - From PCT application to Italian patent \u2013 Revised rules of EPO Boards of Appeal \u2013 Pharma patents in EU - Join our mailing list!","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"[:en]SIBprima July 2019 - From PCT application to Italian patent - Revised rules of EPO Boards of Appeal - Pharma patents in EU[:] -","og_description":"SIBprima July 2019 - From PCT application to Italian patent \u2013 Revised rules of EPO Boards of Appeal \u2013 Pharma patents in EU - Join our mailing list!","og_url":"https:\/\/sib.arvis.dev\/en\/newsletter\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\/","article_published_time":"2019-07-18T10:28:45+00:00","article_modified_time":"2019-07-18T12:34:08+00:00","og_image":[{"width":650,"height":468,"url":"https:\/\/sib.arvis.dev\/wp-content\/uploads\/2019\/07\/Copertina.png","type":"image\/png"}],"author":"Laura Ercoli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Laura Ercoli","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sib.arvis.dev\/en\/newsletter\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\/#article","isPartOf":{"@id":"https:\/\/sib.arvis.dev\/en\/newsletter\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\/"},"author":{"name":"Laura Ercoli","@id":"https:\/\/sib.arvis.dev\/en\/#\/schema\/person\/3988cde84153da4b745510f0712d395b"},"headline":"SIBprima July 2019 – From PCT application to Italian patent – Revised rules of EPO Boards of Appeal – Pharma patents in EU","datePublished":"2019-07-18T10:28:45+00:00","dateModified":"2019-07-18T12:34:08+00:00","mainEntityOfPage":{"@id":"https:\/\/sib.arvis.dev\/en\/newsletter\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\/"},"wordCount":306,"commentCount":0,"image":{"@id":"https:\/\/sib.arvis.dev\/en\/newsletter\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\/#primaryimage"},"thumbnailUrl":"https:\/\/sib.arvis.dev\/wp-content\/uploads\/2019\/07\/Copertina.png","articleSection":["Newsletter"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/sib.arvis.dev\/en\/newsletter\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/sib.arvis.dev\/en\/newsletter\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\/","url":"https:\/\/sib.arvis.dev\/en\/newsletter\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\/","name":"[:en]SIBprima July 2019 - From PCT application to Italian patent - Revised rules of EPO Boards of Appeal - Pharma patents in EU[:] -","isPartOf":{"@id":"https:\/\/sib.arvis.dev\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sib.arvis.dev\/en\/newsletter\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\/#primaryimage"},"image":{"@id":"https:\/\/sib.arvis.dev\/en\/newsletter\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\/#primaryimage"},"thumbnailUrl":"https:\/\/sib.arvis.dev\/wp-content\/uploads\/2019\/07\/Copertina.png","datePublished":"2019-07-18T10:28:45+00:00","dateModified":"2019-07-18T12:34:08+00:00","author":{"@id":"https:\/\/sib.arvis.dev\/en\/#\/schema\/person\/3988cde84153da4b745510f0712d395b"},"description":"SIBprima July 2019 - From PCT application to Italian patent \u2013 Revised rules of EPO Boards of Appeal \u2013 Pharma patents in EU - Join our mailing list!","breadcrumb":{"@id":"https:\/\/sib.arvis.dev\/en\/newsletter\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sib.arvis.dev\/en\/newsletter\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sib.arvis.dev\/en\/newsletter\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\/#primaryimage","url":"https:\/\/sib.arvis.dev\/wp-content\/uploads\/2019\/07\/Copertina.png","contentUrl":"https:\/\/sib.arvis.dev\/wp-content\/uploads\/2019\/07\/Copertina.png","width":650,"height":468,"caption":"from PCT application to Italian patent"},{"@type":"BreadcrumbList","@id":"https:\/\/sib.arvis.dev\/en\/newsletter\/sibprima-july-2019-from-pct-application-to-italian-patent-revised-rules-of-epo-boards-of-appeal-pharma-patents-eu\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sib.arvis.dev\/en\/home\/?lang=en"},{"@type":"ListItem","position":2,"name":"(English) SIBprima July 2019 – From PCT application to Italian patent – Revised rules of EPO Boards of Appeal – Pharma patents in EU"}]},{"@type":"WebSite","@id":"https:\/\/sib.arvis.dev\/en\/#website","url":"https:\/\/sib.arvis.dev\/en\/","name":"","description":"Intellectual Property since 1882","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sib.arvis.dev\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/sib.arvis.dev\/en\/#\/schema\/person\/3988cde84153da4b745510f0712d395b","name":"Laura Ercoli","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b585753dc2b199a95f18adfc63fe4f51a86794b5f62f6d6087ebb3cbe49a1fbc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b585753dc2b199a95f18adfc63fe4f51a86794b5f62f6d6087ebb3cbe49a1fbc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b585753dc2b199a95f18adfc63fe4f51a86794b5f62f6d6087ebb3cbe49a1fbc?s=96&d=mm&r=g","caption":"Laura Ercoli"},"url":"https:\/\/sib.arvis.dev\/en\/author\/lercoli\/"}]}},"_links":{"self":[{"href":"https:\/\/sib.arvis.dev\/en\/wp-json\/wp\/v2\/posts\/10429","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sib.arvis.dev\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sib.arvis.dev\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sib.arvis.dev\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/sib.arvis.dev\/en\/wp-json\/wp\/v2\/comments?post=10429"}],"version-history":[{"count":20,"href":"https:\/\/sib.arvis.dev\/en\/wp-json\/wp\/v2\/posts\/10429\/revisions"}],"predecessor-version":[{"id":10454,"href":"https:\/\/sib.arvis.dev\/en\/wp-json\/wp\/v2\/posts\/10429\/revisions\/10454"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sib.arvis.dev\/en\/wp-json\/wp\/v2\/media\/10396"}],"wp:attachment":[{"href":"https:\/\/sib.arvis.dev\/en\/wp-json\/wp\/v2\/media?parent=10429"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sib.arvis.dev\/en\/wp-json\/wp\/v2\/categories?post=10429"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sib.arvis.dev\/en\/wp-json\/wp\/v2\/tags?post=10429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}